The Study of Business Model of the Pharmaceutical Company in Taiwan : Application of the Hafeez Core Competence Model

• Main Authors: Ting-Yi Chiang, 江庭誼
• Other Authors: Shiuh-Nan Hwang
• Format: Others
• Language: zh-TW
• Published: 2005
• Online Access: http://ndltd.ncl.edu.tw/handle/11750405560860066108

碩士 === 銘傳大學 === 管理研究所碩士在職專班 === 93 === The pharmaceutical company in Taiwan is being placed in an environment of internal revolt and foreign invasion now, versusing inside face the people acceptance of persons usage import medicine, the small scale market, no regulation limited, the limitation by the National Health Insurance program, the changeable government policy and legal, impact of Taiwan joins the World Trade Organization (WTO), as well as data exclusive protection impact and so on. Facing the transnational pharmaceutical company unceasing merge, make the the pharmaceutical company in Taiwan facing the ruthless competition. However, how find out the core competitive advantage, promote the business performance, having already become brooks no delay the matter. This study takes three pharmaceutical companies in Taiwan as the study object, adopting the case studies method of the quality study, providing for the resources theories as base (Wernerfelt, 1984; Prahalad and Hamel, 1990; Barney, 1991; Grant, 1991; Amit and Schoemaker, 1993; Teece et al., 1990, 1997; Sanchez and Heene, 1997), by means of secondary information collecting, interviewed with nine experts and applied the Hafeez et al. (2002) core competence model, in the union finance five forces analysis, discusses the pharmaceutical companies in Taiwan to have any type core competence then to be allowed to have the high business performance. For again auxiliary by cases through interviewing, discusses the business present situation and the business strategy of the pharmaceutical company in Taiwan, and then developing can promote the business model of business performance in the pharmaceutical company in Taiwan. The main findings of this study can be described as follows: 1. Classified as weak research and development ability of the pharmaceutical company in Taiwan, by using the execution bioequivalence study (BE) to obtains the bioequivalence generic license. Simultaneously grasps the control drug price, as well as marketing ability of below regional hospital, clinic and drug store channels, then is advantageous the company’s survival and development. The intermediate stage can first carry on the research and development from technical threshold and investment cost lower new formulation and obtain the new formulation license, then is advantageous promotion to the business performance. 2. The pharmaceutical company in Taiwan should depend on own scale and the resources ability, simultaneously, coordinates own core competence, grasps the market tendency, unceasingly innovates research and development the new product, and matches the different marketing to take and the business strategy, then can in the pharmaceutical industry, find out own niche and the most optimal business model. 3. The pharmaceutical company in Taiwan has new drug research and development ability of the new chemical entity and the new indication and so on, the affiliation by obtains the new drug license and the success market area separates and the product positioning strategy, and grasps brand management, customer service and marketing ability of medical center channel and so on, then has the high business performance. According the results of this study, to develop the business model and business strategy of the pharmaceutical industry in Taiwan should be base on the new drug development strategy. Aim to the new drug development strategy, start from generic bioequivalence drugs production then transformed to develop new formulations, new therapeutic complex formulations, new delivery system, or new application of old drugs, new formulation design, new indication development and specific raw material processing and so on, ising currently can go more of strategy. Meanwhile, we should adopt to focus strategy, product diversification strategy, throwing a sprat to catch a whale, and following the sequence to move on strategy. The business model of the pharmaceutical company in Taiwan, should to first lay the foundation primary, besides the maintenance basic earning, must put into the resources in the innovation research and development again, and can by the economic business model of 『the virtual integration pharmaceutical company』, namely the profession outsources and the division of labor and so on, adopt the steady growth strategy, not only can reduce the risk, simultaneously can promote the competitive force and has the higher business performance. Future can expands through the international marketing ability development again, making the pharmaceutical company in Taiwan not only can be allowed to continue forever the business and the development, will be able to hope the pharmaceutical company in Taiwan will become take Taiwan as the research and development base original development pharmaceutical company.